BioSpace News Archive

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the diagnosis of COVID-19 and Influenza A or B (flu).

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2020 financial results on Thursday, October 29, 2020 . Insmed management will host a conference call for investors begi

Astarte Medical, a precision nutrition company focused on delivering digital tools and diagnostics to improve outcomes in the first 1000 days of life, announced today that the United Stat

Castlight Health, Inc. (NYSE: CSLT), the leading healthcare navigation platform, today announced the addition of three new seasoned executives to its leadership team: Richa Gupta, Chief People Officer, Vijay Anand, Executive Vice President of Engineering, and Angel Rosa, Senior Vice President of Customer Experience

The National Kidney Foundation (NKF) is pleased to announce the appointment of Anthony E. Tuggle as Chair of its National Board of Directors. Tuggle who has served as Chair-elect for the past two years, steps into the leadership role as the term of John Gerzema ends.

Ashvattha Therapeutics Presents Preclinical Data at the American Society of Nephrology (ASN) Virtual Kidney Week 2020 - Expansion of targeting ability of HDTs into renal macrophages enabling targeted treatment of kidney diseases including renal cell carcinoma

Proscia®, a leading provider of digital and computational pathology solutions, today announced that the Joint Pathology Center (JPC), the premiere pathology reference center for the U.S. government, has selected Proscia’s Concentriq® platform for a complete transformation of its pathology practice.

Today, the Cystic Fibrosis Foundation announced it is expanding its research collaboration with Synspira Therapeutics Inc., committing up to $14 million in additional funding to develop a non-porcine enzyme replacement therapy and a novel treatment to help fight drug-resistant infections. The new fun

Axonics ® Launches ARTISTRY Study to Collect and Analyze Real-World Data of Patients Implanted with the Axonics r-SNM System ARTISTRY will enroll up to 300 patients across 30 centers in North America and include patients across all four clinical indications for Axonics Therapy

Combination of automation and technology-enabled services supports more cost-effective workflows and expanded distribution models